K3 Business Technology Group (KBT)

Sector:

IT Services

 87.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 126.00p
  • 52 Week Low: 86.67p
  • Currency: UK Pounds
  • Shares Issued: 44.73m
  • Volume: 0
  • Market Cap: £39.14m
  • RiskGrade: 128

Director dealings: Genus announces new CEO's compensation, AstraZeneca chair spends £0.23m

By Josh White

Date: Tuesday 02 May 2023

LONDON (ShareCast) - (Sharecast News) - Livestock genetics company Genus saw its shares weaken on Tuesday afternoon after it announced the agreed reward arrangements for its incoming CEO, Jorgen Kokke.
Under the shareholder-approved remuneration policy, Kokke would receive a basic annual salary of $825,000, along with a pension contribution worth 6% of his salary.

Additionally, he would receive payments of £4m, mostly in Genus share awards, as compensation for incentives he held at his previous company, Ingredion.

He would also be eligible for an annual bonus of up to 200% of his salary, with one-third of any bonus paid deferred into shares, and a long-term incentive award of 400% of his salary in September, subject to performance targets and a two-year holding period.

At 1301 BST, shares in Genus were down 0.22% at 2,682p.

K3 Business Technology Group, meanwhile, was in the red after Kestrel Partners acquired 76,564 ordinary shares at an average price of £1.10 per share on 21 April.

Kestrel is indirectly holding voting rights over 26.4% of the company's issued share capital.

On 28 April, Kestrel acquired an additional 2,027 shares at an average price of £1.10 apiece, increasing its indirect voting rights to 26.41% of the company's issued share capital.

K3 said non-executive director Oliver Scott is a partner of Kestrel, and holds a beneficial interest in one of Kestrel's clients, which was deemed to have a beneficial interest in Kestrel's entire legal holding in the company.

At 1052 BST, shares in K3 Business Technology Group were down 2.22% at 110p.

Pharmaceuticals giant AstraZeneca was also in focus after its non-executive chair Michel Demaré purchased 2,000 of its ordinary shares on 28 April, at a price of £117.01 per share, for a total value of £234,020.

At 1307 BST, shares in AstraZeneca were down 0.14% at 11,730p.

Finally, ix Net Zero, an investing company focusing on energy transition and sustainability in the built environment, saw its shares slide despite one of its non-executive directors, Patricia McCall, buying 20,000 shares on 28 April.

McCall paid 13p per share, for a total value of £2,600.

Following this purchase, McCall owned 63,139 ordinary shares, representing 0.1% of the company's shares in issue.

At 1231 BST, shares in ix Net Zero were down 10.42% at 16.12p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

KBT Market Data

Currency UK Pounds
Share Price 87.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 126.00p
52 Week Low 86.67p
Volume 0
Shares Issued 44.73m
Market Cap £39.14m
RiskGrade 128

KBT Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
82.64% below the market average82.64% below the market average82.64% below the market average82.64% below the market average82.64% below the market average
6.02% above the sector average6.02% above the sector average6.02% above the sector average6.02% above the sector average6.02% above the sector average
Price Trend
67.14% below the market average67.14% below the market average67.14% below the market average67.14% below the market average67.14% below the market average
80.22% below the sector average80.22% below the sector average80.22% below the sector average80.22% below the sector average80.22% below the sector average
Income Not Available
Growth
46.54% below the market average46.54% below the market average46.54% below the market average46.54% below the market average46.54% below the market average
56.63% below the sector average56.63% below the sector average56.63% below the sector average56.63% below the sector average56.63% below the sector average

KBT Dividends

  Latest Previous
  Final Final
Ex-Div 16-May-19 17-May-18
Paid 14-Jun-19 15-Jun-18
Amount 1.54p 1.40p

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

KBT Key Personnel

CEO Eric Dodd
CFO Lavinia Alderson

Top of Page